Evidence map›Paper›PMID 37931105›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Controlling donor and newborn neuron migration and maturation in the eye through microenvironment engineering.

Jonathan R Soucy, Levi Todd, Emil Kriukov, Monichan Phay, Volha V Malechka, John Dayron Rivera, Thomas A Reh, Petr Baranov

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Hopx(+) optic nerve head-astrocytes counter neuronal stress and glaucoma damage.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The neuroimmune interface in retinal regeneration.Progress in retinal and eye research · 2025
    Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jonathan R SoucyThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.ORCID 0000-0003-1236-1279
Levi ToddDepartment of Biological Structure, University of Washington, Seattle, WA 98195.ORCID 0000-0003-2561-7675
Emil KriukovThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.
Monichan PhayThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.
Volha V MalechkaThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.
John Dayron RiveraThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.
Thomas A RehDepartment of Biological Structure, University of Washington, Seattle, WA 98195.
Petr BaranovThe Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114.ORCID 0000-0002-5526-7058
Massachusetts Eye and Ear Infirmary · USUniversity of Washington · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Tobias Elze · 1985 to 2026
$25.5M
Retinal Ganglion Cell Replacement in Clinically Relevant Models of Optic NeuropathyU24EY029893 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARANOV, PETR, REX, TONIA S · 2018 to 2022
$7.2M
Supplement to EY021482 to carry out a screen for retinal regeneration using CRISPR-Cas9 gene activation.R01EY021482 · NEI · UNIVERSITY OF WASHINGTON · PI THOMAS A REH · 2011 to 2026
$6.3M
Training Program in the Molecular Bases of Eye DiseasesT32EY007145 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore, MEREDITH GREGORY-KSANDER · 1997 to 2026
$4.5M
Investigation of the neuroimmune axis in retinal regeneration.K99EY033402 · NEI · UNIVERSITY OF WASHINGTON · PI TODD, LEVI J. · 2022 to 2023
$240k
Regulating cell-cell interactions to improve donor retinal ganglion cell integrationF32EY033211 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI SOUCY, JONATHAN R · 2022 to 2024
$222k
NEI NIH HHS F32 EY033211NEI NIH HHS K99 EY033402NEI NIH HHS L70 EY034355NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY021482NEI NIH HHS T32 EY007145NEI NIH HHS U24 EY029893
6 · The paper itself

Abstract

Ongoing cell therapy trials have demonstrated the need for precision control of donor cell behavior within the recipient tissue. We present a methodology to guide stem cell-derived and endogenously regenerated neurons by engineering the microenvironment. Being an "approachable part of the brain," the eye provides a unique opportunity to study neuron fate and function within the central nervous system. Here, we focused on retinal ganglion cells (RGCs)-the neurons in the retina are irreversibly lost in glaucoma and other optic neuropathies but can potentially be replaced through transplantation or reprogramming. One of the significant barriers to successful RGC integration into the existing mature retinal circuitry is cell migration toward their natural position in the retina. Our in silico analysis of the single-cell transcriptome of the developing human retina identified six receptor-ligand candidates, which were tested in functional in vitro assays for their ability to guide human stem cell-derived RGCs. We used our lead molecule, SDF1, to engineer an artificial gradient in the retina, which led to a 2.7-fold increase in donor RGC migration into the ganglion cell layer (GCL) and a 3.3-fold increase in the displacement of newborn RGCs out of the inner nuclear layer. Only donor RGCs that migrated into the GCL were found to express mature RGC markers, indicating the importance of proper structure integration. Together, these results describe an "in silico-in vitro-in vivo" framework for identifying, selecting, and applying soluble ligands to control donor cell function after transplantation.

Indexed as

RetinaRetinal Ganglion CellsCell MovementHumansInfant, NewbornNeurogenesisStem Cellschemokinesglaucomaretinal organoidsstem cellstransplantation

Identifiers

PMID37931105
PMCPMC10655587
OpenAlexW4388406906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.